close

Bharat Biotech to collaborate with Hilleman to develop cholera vaccine

Hillchol was designed at the University of Gothenburg in Sweden and subsequently developed by Hilleman Labs

BS Reporter Hyderabad
drugs, medicines,
Premium

Representative Image

Hilleman Laboratories announced on Wednesday that it will collaborate with Hyderabad-based vaccine maker Bharat Biotech International Limited (BBIL) for further development, manufacture and commercialisation of its next generation oral cholera vaccine, Hillchol.
Hillchol was designed at the University of Gothenburg in Sweden and subsequently developed by Hilleman Labs. The development process included demonstration of safety and imnmunogenicity in an age de-escalating phase I/II clinical trial conducted in Bangladesh.
For further development of the vaccine candidate, Hilleman Labs has entered into a licensing and manufacturing agreement with BBIL, which will scale the manufacturing process to commercial stage and establish product specifications required for WHO pre-qualification.
Or

Also Read

Bharat Biotech to acquire GSK's Indian vaccine firm for undisclosed sum

Bharat Biotech to buy GSK's Indian arm that produces anti-rabies vaccine

NCLT questions Sterling Biotech lenders on accepting deal from promoters

NCLT rebukes Sterling Biotech resolution professional, demands explanation

Lenders plan to appeal against Sterling Biotech liquidation order

HDFC Life and IvyCamp to help startups create opportunities in insurance

Trump Tower developer Lodha battles bond slump amid cash crunch

PE inflows into realty up 26% to Rs 28,000 crore in first half of 2019

LG to introduce five devices under India-first W series of smartphones

Auto components get public utility status in TN, workers can't go on strike

First Published: Jun 26 2019 | 3:49 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to read more on Business-Standard.com